Keyword: Patent Trial and Appeal Board
An appeals court rejected Allergan's attempt to protect Restasis patents with sovereign immunity, clearing the way for generics.
Allergan made countless headlines last year with its scheme to protect Restasis from patent challenge by striking a licensing deal with the Saint Regis Mohawk Tribe. But thanks to a separate federal court decision, the company faces the prospect of early generics anyway.
Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.
Novartis loses Gilenya patent appeal, clearing way for early copies of the $3 billion multiple sclerosis med.
Biogen has prevailed in a patent squabble with Forward Pharma over Tecfidera, but can the decision actually help the Big Biotech dodge generic rivals?
Acorda Therapeutics’ IP protection on Ampyra may have held up against an administrative patent challenge, but it didn't do the same in court.